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S_ary The primary chemosensitivity of 16 highly malignant xenografted human soft-tissue sarcomas to
ifosfamide, dacarbazine, adriamycin and cisplatin and the development of secondary drug resistance in two
chemosensitive sarcoma cell lines was tested in the xenograft system. Single-dose, single-agent treatments with
350 mg kg- ' ifosfamide, 200 mg kg-' dacarbazine, 10 mg kg ' doxorubicin and 6.6 mg kg- ' cisplatin were
administered and response measured as specific growth delay. Since ifosfamide induced unexpectedly higher
toxicity, response was corrected based on the shape of the dose-response curve for ifosfamide. Taking a
specific growth delay >3 as the cut-off point for chemosensitivity, ifosfamide, dacarbazine, doxorubicin and
cisplatin were effective in 10/16, 4/16, 2/16 and 1/16 sarcoma cell lines respectively. Five out of 16 sarcoma cell
lines were resistant to all tested drugs. Ifosfamide-resistant sarcoma lines were also resistant to doxorubicin
and cisplatin, indicating a high degree of cross-resistance. Dacarbazine was still effective in 1/6 ifosfamide-
resistant sarcoma cell lines. Secondary drug resistance developed slowly after doxorubicin and ifosfamide
pretreatments at moderate selection pressure and developed rapidly after dacarbazine pretreatment at high
selection pressure.
Human xenografts in nude mice have been extensively used
to evaluate the efficacy of new anti-cancer drugs in a pre-
clinical model, based on the notion that xenografts most
closely mimic the situation in patients. The predictive value
of the xenograft model was supported by the observation
that generally good correlations between the response in
patients and in xenografts of the same patients were found
(Shorthouse et al., 1980, 1982; Giovanella et al., 1983; Steel
et al., 1983; Osieka, 1984; Mattern et al., 1988a; Fiebig et al.,
1992). However, since human tumours exhibit considerable
heterogeneity of tumour biology and chemosensitivity
between and within different tumour histologies, it has been
proposed that a panel of tumours of various histological
types should be used to predict the potential of new drugs
(Fodstad et al., 1985; Winogard et al., 1988). Only a few
human soft-tissue sarcoma xenografts have been available for
preclinically test and were not used in the drug screening
programmes of the National Cancer Institute and the
EORTC New Drug Development Office. We were able to
establish a panel of more than 30 well-characterised human
soft-tissue sarcoma cell lines as xenografts in nude mice. The
poor clinical results of adjuvant and neoadjuvant chemo-
therapies in soft-tissue sarcomas of adults indicate a high
degree of primary or a rapid development of secondary drug
resistance to known drugs. In a preliminary series of investi-
gations we were interested in evaluating whether the same
degree of resistance would be expressed in soft-tissue sar-
coma xenografts, providing a useful panel of tumours for
preclinical tests. Therefore, the efficacies of ifosfamide (IFO),
doxorubicin (DOX), dacarbazine (DTIC) and cisplatin
(DDP), four drugs with known clinical response rates, were
tested in 16 sarcoma cell lines of the panel, in order to
compare the patterns of sensitivities to the clinical data and
to select sensitive and resistant cell lines for further investiga-
tions. Furthermore, two chemosensitive soft-tissue sarcoma
cell lines were used to monitor the development of secondary
drug resistance to IFO, DOX and DTIC in vivo.
Materias and methods
Sixteen grade III human soft-tissue sarcoma cell lines were
used for the studies. Table I summarises the histology and
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origin of the tumour lines, established between 1985 and
1991 from patients that had not received chemotherapy
before. The cell lines were propagated in NMRI nu/nu nude
mice for several passages and characterised by means of flow
cytometry and lactate dehydrogenase (LDH) and glucose-6
phosphate dehydrogenase (G6PD) isoenzyme patterns. Com-
paring late and early passages, these parameters remained
constant in all tumour lines except ES3, in which a loss of all
human isoenzymes occurred, after three pretreatments with
IFO. Therefore, the data on ES3 after pretreatment with IFO
were excluded from the analysis. For experiments, mice bred
in a defined flora were maintained in the Department of
Radiation Oncology of Essen University in laminar air flows,
and were fed high-calorie laboratory food and drank water
supplemented with chlortetracycine (Og1-') and potassium
sorbate (1.35 g 1') acidified to a pH of 3.0 with hydrochloric
acid. At 2 week intervals, erythromycin was added to the
drinking water. To minimise the residual immune response of
the nude mice against xenografts, all mice underwent a 5 Gy
whole-body irradiation from a cobalt-0 source (dose
rate = 0.17 Gymin1) 1 day before tumour transplanta-
tions.
For experiments, tumour chunks derived from a source
tumour were transplanted subcutaneously into the right flank
of 5- to 7-week-old nude mice. All animal experiments were
performed according to the institutional guidelines. Animals
were randomly assigned to control and treatment groups
when a tumour volume of 150-200 mm' was reached. Each
treatment and control group contained 5-8 mice. The
tumours were scored twice a week and the volume was
calculated as V = 0.5 (a x b2), where a and b are the long and
short axis respectively.
Primary sensitivity testing
In order to compare the efficacy of the different drugs, we
planned to administer isotoxic dose levels corresponding to
the LD0 o30. For DTIC and DDP these values were based on
the experience of Osieka et al. (1984), who worked in parallel
in the same institution on the identical strain of NMR1 nude
mice, whereas for DOX and IFO we relied on data from our
laboratory. According to these data, the animals bearing
tumours of all 16 tumour lines received single-dose, single-
agent treatments with l0mgkg-' DOX, 350mgkg-' IFO,
200 mgkg' DTIC, and 6.6 mgkg-' DDP. IFO, DTIC and
DDP were injected intraperitoneally (i.p.), whereas DOX was
administered intravenously (i.v.) because it induces severe
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Table I Characteristics of the investigated panel of soft-tissue sarcomas
Histologp
Malignant fibrous histiocytoma
Malignant fibrous histiocytoma
Malignant fibrous histiocytoma
Malignant fibrous histiocytoma
Leiomyosarcoma
Leiomyosarcoma
Leiomyosarcoma
Neurofibrosarcoma
Neurofibrosarcoma
Neurofibrosarcoma
Spindle cell sarcoma
Spindle cell sarcoma
Spindle cell sarcoma
Neurogenic sarcoma
Liposarcoma
Malignant paraganglioma
aMean ± indicates 95% confidence hmits.
Origin
Recurrence of the primary
Primary
Primary
Recurrence of the primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Metastasis
Primary
Metastasis
DNA
Grading content
3 Aneuploid
3 Aneuploid
3 Aneuploid
3 Tetraploid
3 Aneuploid
3 Diploid
3 Aneuploid
3 Tetraploid
3 Aneuploid
3 Aneuploid
3 Diploid
3 Diploid
3 Diploid
3 Aneuploid
3 Aneuploid
3 Aneuploid
peritonitis after i.p. injection. IFO-treated animals received a
simultaneous dose of 70 mg kg-' mesna i.p. to reduce
urotoxic side-effects. Additionally, in two sarcoma cell lines
(ENE2 and ES3) dose-response curves were generated using
graded doses of IFO, DOX and DTIC: 125-425mgkg-',
5-15mgkg-', and 50-200mgkg-' respectively. Animals
allocated to IFO received in addition mesna i.p. correspond-
ing to 20% of the IFO dose.
Induction ofsecondary drug resistance
The development of secondary drug resistance was tested in
two sarcoma cell lines (ENE2 and ES3) that were pimarily
sensitive to DOX, IFO and DTIC. For the induction of
resistance, the regrowing tumours after chemotherapy with
DOX, IFO, or DTIC were excised and transplanted into
successive generations of nude mice and retreated with the
same drug. Five to eight mice were used for each treatment
group and another five mice served as control group in each
passage. The dose levels for all drugs were the same as in the
primary sensitivity testing and kept constant for all subse-
quent treatments. This procedure was repeated at least six
times for all drugs and up to 13 times for DOX in the ENE2
sarcoma cell line. Sufficient data to assess response were
recorded in all passages except for the third, ninth and tenth
passages in the ENE2 tumour line after DOX treatment, for
which the number ofanimals reaching the end point of4-fold
initial volume was insufficient.
Assessment oftoxicity
The dose lethal to 50% of treated animals (LD5() was deter-
mined prior to testing chemosensitivity for DOX and IFO.
NMRI nu/nu mice received graded doses between 2.5 and
15mgkg-' DOX i.v. or between 200 and 805 mgkg-' IFO
i.p. and 20% of the IFO dose mesna i.p. Thirty-six animals
were used for each drug and lethality was recorded at day 30.
The quantal data were analysed by using a logit regression in
order to estimate the LD 030 and the LD,030.
In addition, the toxicity of all drugs was determined during
the primary sensitivity testing. Survival of mice after admini-
stration of chemotherapy in the primary sensitivity testing
was used as a base to estimate lethality at day 30 for all
treatment groups according to the Kaplan and Meier
method. Data from mice with recurring tumours reaching
4-fold the initial tumour volume before day 30 were cen-
sored. Furthermore, body weight was recorded 2-3 times a
week as a second measure of toxicity.
Data analysis
After chemotherapy, all tumours were scored twice a week
until either a regrowth to at least four times the initial
volume was observed or experiments were terminated at day
90 after treatment. Growth delay (GD) was calculated as the
difference in the growth time of the treatment group (GTt)
and the control group (GTc) to four times the initial tumour
volume (GD = GTt - GTc). Specific growth delay (SGD)
was calculated as: SGD = (GTt - GTc)/TDTc, where TDTc
is the tumour doubling time of untreated tumour in control
animals. In case of intercurrent death of animals or cure
events, median GD and SGD were corrected according to a
previously described procedure (Stuschke et al., 1990) based
on the product limit method of Kaplan and Meier. Tumour
cell lines exhibiting an SGD of more than 3 were considered
to be sensitive to treatment. SGD divided by log,0(2) (SGD/
3.32) can be used to estimate logl0 tumour cell kill from SGD
data.
Results
The results of the LD experiments for IFO and DOX and
the observed toxicity in tumour-bearing animals during the
assessment of tumour chemosensitivity are summarised in
Table II. The administered single doses for all drugs were
thought to be isotoxic at the LD,030 level as predicted from
lethality experiments and literature data. However, DOX,
DTIC, and DDP induced fewer toxic deaths (4-9%), where-
as IFO caused significantly higher lethality (21%) than
predicted from lethality experiments (Figure 1). Maximum
weight loss and duration of weight loss were similar for
DOX, DTIC and DDP, whereas IFO at 350 mg kg-' induced
a significantly higher median weight loss (P<0.005) and a
longer duration ofweight loss (P<0.05) than the other drugs
(Table II).
Dose-response curves were generated for IFO, DTIC and
DOX in the two sarcoma cell lines (ENE2 and ES3), which
were sensitive to all three drugs, in order to assess the shape
and the steepness of dose-response. The dose-response rela-
tionship was almost linear in the tested dose range for all
drugs (Figures 2 and 3). Extrapolation of response in the
low-dose range also indicated a linear relationship for DOX
and IFO, but a non-linear response with a kind of plateau at
high-dose levels for DTIC. Doses below 200 mg of IFO,
150 mg of DTIC and 7.5 mg of DOX induced no significant
weight loss and no intercurrent death. In these experiments
16 animals received a dose of 275 mg kg-' IFO. The median
maxiimal weight loss in these animals was 3%, and only one
toxic death (6%) was observed. Lethality data and weight loss
for the different treatments are summarised in Table II.
According to these observations 275 mg kg-' IFO was
regarded as approximately isotoxic to 10 mg kg' DOX
200 mg kg-' DTIC and 6.6 mg kg-' DDP.
The tumour doubling times (TDTs) ranged from 2.2 to
Cell line
EF8
EFIO
EF13
EF14
EL5
EL8
EL9
EN2
EN3
EN4
ESI
ES2
ES3
ENE2
E18
EPGI
Twnour
passage
35
15
1
5
40
14
16
46
7
1
27
21
13
6
5
8
Tumoour
doubling
time (davs)a
3.0 ± 0.3
2.2 ± 0.2
16.8 ± 5.8
3.2 ± 0.1
4.9 ± 0.6
3.4 ± 0.5
3.4 ± 0.3
2.6 ± 0.5
6.0 ± 0.5
13.0 ± 5.6
5.7 ± 0.7
3.8 ± 0.8
2.7 ± 0.4
2.9 ± 0.2
2.4 ± 0.4
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Table H Treatment-induced toxicity
DOX DTIC DDP IFO
Lethality experiments
LD50 30 14.4 mg NA NA 563 mg
95% CL 13.2-15.9 mg 490-630 mg
LDIo 30 9.8 mg NA NA 358 mg
95% CL 6.7-11.4 mg 259-495 mg
Weight loss
10mg DOX 200mg DTIC 6.6mg DDP 350mg IFO 275mg IFO
Weight lossa 3.9% 2.1% 3.6% 8.2%b 3.1%
Nadir of loss Day 8 Day 9 Day 9 Day 7 Day 8
Recovery time to 8 days 10 days 8 days 12 days 9 days
initial weight
Toxic deathsc 4.4% 6.1% 9.0% 20.8%b 6.3%
n 60 60 66 64 16
'Maximal mean weight loss after treatment. bSignificantly different (P <0.005), whereas no
significant differences were found between all other groups. clntercurrent, non-tumour-related deaths
until day 30 after treatment. DOX, doxorubicin; DTIC, dacarbazine; DDP, cisplatin; IFO, ifosfamide;
doses: mg kg-' body weight; LD_%30, lethal dose for 50% of animals within 30 days; LD,O30, lethal dose
for 10% of animals within 30 days; CL, confidence limit; NA, not available.
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Figwe 1 Survival of mice after administration of 10mgkg-'
doxorubicin (DOX), 200 mg kg- dacarbazine (DTIC),
6.6mgkg-' cisplatin (DDP) and 350mg kg-' ifosfamide (IFO)
in the primary sensitivity testing was recorded for all treatment
groups according to the Kaplan and Meier method. Data from
mice with recurring tumours reaching four times the initial
tumour volume before day 30 were censored.
16.8 days (Table I), however in most of the tumour lines
(10/16) the TDT was <4 days.
The primary response to chemotherapy measured as SGD
is summarised in Table III and illustrated in Figure 4. Based
on the observation of linear dose-response relationships
between 125 mg kg- 1 and 350 mg kg-' for IFO in ENE2 and
ES3, the SGD at 275 mg kg-' (isotoxicity to DOX, DDP and
DTIC) was calculated from the results at 350 mgkg' IFO
assuming linear dose-response relationships for all tumour
lines. The open bars in Figure 4 and the values for
275 mg kg-' IFO in Table III indicate the calculated SGD at
275 mg kg-' IFO.
Taking an SGD>3 as the cut-off for chemosensitivity,
350mgkg-' IFO was effective in 11/16 and at 275mgkg1
(calculated) in 10/16 sarcoma cell lines. DTIC, DOX and
DDP were effective in 4/16, 2/16 and 1/16 sarcoma cell lines
respectively. IFO-resistant cell lines were always resistant to
DOX and DDP. DTIC was still effective in 1/6 IFO-resistant
sarcoma cell lines. The frequency of multidrug-sensitive sar-
coma cell lines is shown in Table IV. In a multivariate
analysis, histology, DNA content and TDT were insignificant
factors for the prediction of tumour response.
Figure 5 illustrates the development of secondary drug
resistance to IFO, DOX and DTIC in the ENE2 and the ES3
sarcoma cell lines. The tumour doubling times of the parent
xenografts were 2.6 and 2.7 days for ENE2 and ES3 respec-
tively. In some of the control groups during subsequent
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Fuw e 2 Graded dose levels of doxorubicin (0, DOX), ifos-
famide (A, IFO) and daarbaine (*, DTIC) were administered
and specific growth delay recorded for 5-8 animals bearing the
ENE2 sarcoma cell line in each treatment group. Bars idicate
95% confidence intervals.
treatments, significant changes in the tumour doubling times
were observed. However, these changes remained so inconsis-
tent that no correlation between the number of pretreatments
and a decrease or increase in tumour doubling times was
found. Whereas consecutive treatments with DOX or IFO
induced a slowly developing, unstable and incomplete secon-
dary resistance, the secondary resistance caused by DTIC
developed rapidly and was complete and stable after 3-4
pretreatments.
Dimcssio
The pattern of response towards chemotherapeutic drugs
with known clinical effiacy was investigated in a panel of 16
xenografted highly malignant human soft-tissue sarcomas.
The results of the primary sensitivity testing are summarsed
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in Figure 4 and Table III. Interpreting the data one has to be
aware that IFO induced significantly higher toxicity in terms
of weight loss (Table II) and lethality (Figure 1) as compared
with the other tested drugs. Whereas IFO was more toxic
than predicted by a previously recorded LD_% experiment,
DOX, DTIC and DDP were less toxic than predicted. This
underlines the problem of a reliable dose assessment in the
low-toxicity range (LD1,030) from LD50 experiments, especially
since toxicity varies in different laboratories and mice
strains.
To evaluate whether the efficacy of IFO might be overesti-
mated because of its higher toxicity compared with the other
tested drugs, dose-response curves were recorded for two
chemosensitive sarcoma cell lines. Linear dose-response rela-
tionships were found for DOX and IFO (Figures 2 and 3),
whereas a non-linear relationship was observed for DTIC. In
ES3 (wild type)
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these experiments a dose of 275 mg kg-' IFO was found to
be approximately isotoxic to 10mg kg-' DOX, 200 mg kg-'
DTIC and 6.6mg kg-' DDP (Table II). Since dose-response
was linear for IFO, it was reasonable to calculate the
expected response for all sarcoma cell lines at the isotoxic
dose of 275 mg kg' IFO, as illustrated in Figure 4.
Taking an SGD> 3 as the cut-off point for chemosensi-
tivity, IFO was, according to the estimated response at the
reduced dose level, still effective in 63% (10/16) and thus by
far the most efficient drug in the panel of the tested sar-
comas. DTIC was extremely effective in 25% (4/16) of the
tumour cell lines but did not show any effect in the others;
DOX induced only moderate anti-tumour activity (2/16);
DDP was ineffective (1/16).
The efficacy of IFO in sarcoma xenografts (Table III and
Figure 4) is in good agreement with clinically reported re-
sponse rates (Stuart-Harris et al., 1983; Klein et al., 1984;
Antman et al., 1985; Wiltshaw et al., 1986) of about 40%.
Boven et al. (1989) found four out of five human sarcoma
xenografts to be sensitive to IFO in the only other study on
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Fugwe 3 Graded dose levels of doxorubicin (0, DOX), ifos-
famide (A, IFO) and dacarbazine (*, DTIC) were administered
and specific growth delay recorded for 5-8 animals bearing the
ES3 sarcoma cell line in each treatment group. Bars indicate 95%
confidence intervals.
DOX (mg)
Figwe 4 The specific growth delay (SGD) of 16 soft-tissue
sarcomas induced by cisplatin (DDP), doxorubicin (DOX), ifos-
famide (IFO) and dacarbazine (DTIC) has been plotted for all
sarcoma cell lines. The values in parentheses indicate the level of
toxicity induced by the administered dose. LD5 = 5% toxic
deaths within 30 days after application. LD20 = 20% toxic deaths
within 30 days after application. LD5* = calculated response at a
toxicity corresponding to the LD5 based on linear dose-response
relationships that were observed for ifosfamide. Solid bars
indicate measured response; open bars calculated response.
Table m Specific growth delay of 16 tested sarcoma lines
350 mg Ifosfanide 275 mg Dacarbazzine Doxorubicin Cisplatin
Cell line SGD 95% CL SGD SGD 95% CL SGD 95% CL SGD 95% CL
EF8 1.5 0 3.4 1.2' 0.2 0 0.4 0.4 0.1 0.9 0.6 0.4 0.8
EFIO 5.9 4.8 7.0 4.6a 1.3 0 3.2 0.4 0.2 0.6 1.2 0.6 1.8
EF13 >2.6b >2.6 b >2.0 0.1 0 0.6 1.0 0.3 1.7 0 c c
EF14 > 16.9b > 16.9 b > 13.3a 0.3 0.2 0.4 0.3 0.1 0.5 0 c
EL5 7.4 6.2 8.6 5.8a 8.6 7.5 9.7 0.6 0.2 1.0 4.3 3.4 5.2
ELU 3.9 3.3 4.5 3.1a 0.3 0 1.0 1.9 0.5 3.3 0.6 0.1 1.1
EL9 3.4 2.2 4.6 2.7' 24.7 17.6 31.8 0.7 0.5 0.9 0.9 0.4 1.4
EN2 8.5 4.9 12.1 6.7' 0.7 0.2 1.2 0.4 0.1 0.7 0.8 0.5 1.1
EN3 1.7 1.3 2.1 1.3' 0.1 0 0.5 1.2 0.4 2.0 0.5 0 1.0
EN4 >4.3b >4.3 b >3.4a 0 c c 0.9 0 3.1 0.7 0 1.7
ESI 7.1 5.9 8.3 5.6' 0 C C 1.6 0.7 2.5 0.5 0.2 0.8
ES2 4.5 2.5 6.5 3.5a 0 c c 1.5 0.2 2.8 0.3 0 0.6
ES3 8.7 7.2 10.2 6.8 20 16.5 23.5 5.2 4.2 6.2 0.8 0.4 1.2
ENE2 6.9 6.4 7.4 5.4 16.3 15 17.6 8.3 6.1 10.5 0.5 0.2 0.8
E18 2.3 1.7 2.9 1.8a 1.7 0 3.5 0.1 0 0.5 1.0 0 2.1
EPGI 0.9 0.3 1.5 0.7' 0.3 0 0.9 0.6 0 1.2 0.7 0.2 1.2
Specific growth delay (SGD) of 16 soft-tissue sarcomas induced by 350mgkg-' ifosfamide, 10mgkg-' doxorubicin, 200mgkg-'
dacarbazine and 6.6mglkg-' cisplatin. aCalculated reponse at 275mg kg-' ifosfamide based on the observation of linear dose-response
relationships for ifosfamide. bHigh incidence of most likely non-treatment-related late deaths in animals without evidence of recurrent tumour
between day 35 and 50, allowing only for an estimate of the lower confidence limit cConfidence limits (CL) not available.CHEMOSENSMVITY OF HUMAN SARCOMA XENOGRAFTS 33
Table IV Frequencies of multidrug-sensitive sarcoma lines
Nwnber of sarcoma lines
SGD>3
Sensitive to no agents 5
Sensitive to one agent 7
Sensitive to two agents I
Sensitive to three agents 3
Sensitive to four agents 0
Total 16
Sarcoma cell lines were regarded as responsive if a specific growth
delay (SGD) of >3 was observed.
0.
IL)
DTIC
14
12 Responseto 350mgkg 1
IFO
10 ENE2
8
6
4
2
O 1 2 3 4 5 6
Pretreatments with
ifosfamide
DTIC
Fugwe 5 Development of secondary drug resistance in the ENE2
and the ES3 sarcoma cell line after repeated treatments with
doxorubicin (DOX), dacarbazine (DTIC) or ifosfamide (IFO).
The number of consecutive treatments with the same drug is
plotted against the response measured as specific growth
delay.
the efficacy of IFO in sarcoma xenografts that has been
published.
The low response rate (2/16) of DOX in the tested panel of
soft-tissue sarcomas does not reflect the clinical experience of
up to 40% responses in soft-tissue sarcoma patients (Blum,
1975; Pinedo & Verwey, 1985; Rosenberg et al., 1985). Boven
et al. (1989) tested seven human sarcoma lines in the xeno-
graft system and found five to be responsive to DOX.
According to Giuliani et al. (1981), DOX was effective in one
tested sarcoma line. Aamdal et al. (1986) reported an anti-
tumour activity of DOX in 5 out of 12 sarcoma lines in a
subrenal capsular assay. The total DOX doses in these
studies were in the same range as in the present investigation,
although some authors used a 2 day schedule. The use of a
different end point, growth inhibition, in the work of Boven
et al. (1989) or a different assay in the work of Aamdal et al.
(1986) might partly explain the mismatch. However, the
reason for the higher efficacy of DOX in patients and in the
few published xenograft studies compared with our results is
not completely understood.
The efficacy of DTIC against human sarcoma cell lines
has, at least to the knowledge of the authors, not been tested
in an experimental model before. The response rate (25%)
was similar to clinical observations (20%) (Gottlieb et al.,
1976; Bramwell et al., 1979; Greenall et al., 1986), but the
extent of the response in the sensitive cell lines was impres-
sive. SGD values as high as 25 (Table III), corresponding to
an average growth delay of 84 days in one cell line and cure
events in three cell lines, were observed. On the one hand, the
efficacy of DTIC exceeded even the highest effects of IFO
(Figure 4) in the four sensitive cell lines; on the other hand,
in contrast to IFO, almost no effect was seen in all other cell
lines.
DDP had the least effect of all tested drugs. Only one
sarcoma cell line was moderately sensitive (Figure 4, Table
III). Tumour remissions were not observed. The low response
rates of about 10% in clinical studies (Karakouis et al., 1979;
Samson et al., 1979) are reflected in the xenograft data.
Aamdal et al. (1986) reported an anti-tumour activity in 8
out of 12 sarcoma lines for DDP in the subrenal capsular
assay using a slightly higher total dose in a 2 day schedule.
This high response rate might be a result of the very different
assay conditions.
Neither histology, DNA content, nor tumour doubling
time was a predictor of tumour response to any of the
cytostatic drugs. No significant correlation between the
chemosensitivities could be demonstrated. Five out of 16
sarcoma cell lines were resistant to all tested drugs (Table
IV). IFO-resistant sarcomas were with one exception also
resistant to all other drugs. DTIC was the only agent that
was still effective in one IFO-resistant cell line. DOX was
effective in two sarcoma lines, both ofwhich were also highly
responsive to IFO (Table III and Figure 4). In IFO-resistant
sarcoma lines DOX showed not even a moderate anti-tumour
activity, indicating a complete cross-resistance in our data.
Combination therapy with IFO and DOX has in clinical
studies induced response rates of between 24% and 36%
(Dombernowsky et al., 1986; Wiltshaw et al., 1986; Schuitte
et al., 1987) and has not convincingly demonstrated an
advantage compared with monotherapy. The high degree of
cross-resistance revealed by the experimental data is in agree-
ment with this finding.
In the second part of the investigation the development of
secondary drug resistance was monitored in two IFO- and
DOX-sensitive sarcoma xenografts. Since drug delivery in
vivo is inhomogeneous, the concentration of drug to which
tumour ceUs are exposed and exposure time vary over a wide
range, which results in a heterogeneous population of clones
in the regrowing tumours. Environmental factors and interac-
tion between host and tumour ceUs have also been shown to
modify the development of resistance (Teicher et al., 1978;
Moulder et al., 1991). Therefore, human tumour xenografts
represent a clinically relevant in situ model, which might
provide additional information that is not attainable in
vitro.
The response to DTIC decreased rapidly in both tested
sarcoma cell lines (Figure 5). After one pretreatment less
than 50% of the initial efficacy and after 3-4 pretreatments
no detectable response at all was observed. Pretreatments
with DOX or IFO induced a less rapid development of
secondary drug resistance (Figure 5). Depending on the
tumour line, 2-4 pretreatments were necessary to reduce the
response to less than 50% of the initial response, and as
many as 12 pretreatments with DOX had to be administered
before DOX was without demonstrable efficacy (Figure 5).
The selection pressure in these experiments was much lower
for IFO and DOX (SGD = 5-8) than for DTIC (SGD =
16-20). In similar experiments with a human malignant
melanoma, DTIC (Osieka, 1984) was used at a considerably
lower selection pressure (SGD = 5), resulting in still more
than 50% of the initial efficacy after three pretreatments. In
an epidermoid lung cancer cell line, successive treatments
with actinomycin D, DDP and vincristine resulted in a 50%
decrease of response after one, six and four pretreatments
respectively (Mattern et al., 1988b). In this study relatively
low selection pressures (SGD = 2-3) were applied for all
tested drugs, resulting in more than 25% of the initial re-
sponse even after eight pretreatments. According to the
available data the rapidity ofdevelopment of secondary drug
resistance in xenografts is mainly dependent on the extent of34 W. BUDACH et al.
the selection pressure, whereas the tumour cell line and type
of drug appear to be less important. However, too few data
have been accumulated for a conclusive statement and none
of the studies investigated the underlying mechanisms ofdrug
resistance.
The pattern of response towards IFO, DOX, DTIC, and
DDP in the tested panel of human soft-tissue sarcoma xeno-
grafts revealed a high degree of primary resistance and a
rapid development of secondary resistance. This finding
reflects clinical experience and indicates that a useful panel of
tumours for further preclinical evaluation could be estab-
lished. IFO was the most effective drug followed by DTIC
and DOX. DDP showed almost no anti-tumour activity.
One-third of the sarcoma lines were resistant to all tested
drugs, with a high degree of cross-resistance between the
drugs. Secondary drug resistance developed more slowly after
DOX and IFO pretreatments at moderate selection pressure
than after DTIC pretreatment at high selection pressure.
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